تثبيت سعر الذهب أداة!
التاريخية سعر الذهب الفضة
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
|
2018/09/16
| دولار / اونصة | |
| Gold | | |
| Silver | |
Gold سعر الذهب التاريخية التخطيط والرسم البياني
360 يوما الرسم البياني ,
1 Ounce Gold=? USD
Silver فضة السعر الرسم البياني التاريخي والرسم البياني
360 يوما الرسم البياني ,
1 Ounce Silver=? USD
أخبار الذهب:
- 治疗小细胞肺癌新药——Lurbinectedin - pku. edu. cn
Lurbinectedin是一种烷化剂,可与DNA小沟中的鸟嘌呤残基相结合,触发系列反应,最终导致细胞凋亡,从而发挥抗癌作用。本文对Lurbinectedin的作用机制、药代动力学、临床研究和安全性等进行综述。 Keywords Lurbinectedin; 小细胞肺癌; DNA结合物
- 30年磨一剑！小细胞肺癌重磅新药lurbinectin获批上市 - 知乎
从目前公布的Lurbinectedin的各期临床试验来看，其结果优异，尽管没有进行与 拓扑替康 对比的研究试验，但显示出了Lurbinectedin作为SCLC患者二线治疗替代方案的潜力。根据目前获批的二线治疗方案，Lurbinectedin极有可能进入最新的NCCN（美国国立综合癌症网络）SCLC
- A pivotal bridging study of lurbinectedin as second-line . . . - Nature
This single-arm, multi-center clinical trial aimed to evaluate the safety, tolerability, DLT, recommended dose (RD), preliminary efficacy, and pharmacokinetics (PK) characteristics of
- 小细胞肺癌新药！南京绿叶Lurbinectedin获CDE优先审评 - 知乎
lurbinectedin能够为这些患者提供更多治疗选择。lurbinectedin的批准是基于一项纳入105例受试者的临床II期研究数据，客观缓解率（ORR）为主要治疗终点。作为单药疗法，二线单药治疗小细胞肺癌的ORR为35 2％，中位总体生存期（OS）为9 3个月，疾病控制率（DCR）为68 6％。
- Editorial: Trabectedin, lurbinectedin, and other marine-derived . . .
In this special issue entitled “Trabectedin, Lurbinectedin, and other Marine-Derived Anticancer Alkaloids” basic scientists and clinical researchers provide some interesting examples of marine compounds that are already part of the therapeutic armamentarium of the medical oncologists (i e trabectedin and eribulin) or under preclinical and
- Trabectedin and lurbinectedin: Mechanisms of action, clinical impact . . .
The CORAIL phase III trial randomized 442 heavily pretreated patients with platinum‐resistant ovarian cancer to receive either lurbinectedin 3 2 mg m 2 (1-h infusion) 3qwk or investigator choice’s therapy (consisting of either PLD 50 mg m 2 q4wk or topotecan 1 5 mg m 2 on days 1–5 q3wk) () Median PFS was 3 5 months in the lurbinectedin arm versus 3 6 months in the control arm (HR = 1 057
- A pivotal bridging study of lurbinectedin as second-line . . . - Nature
of lurbinectedin as second‑line therapy in Chinese patients with small cell lung cancer Ying Cheng1*, Chunjiao Wu1, Lin Wu2, Jun Zhao3, Yanqiu Zhao4, Lulu Chen1, Ying Xin1,
- Lurbinectedin: an FDA-approved inducer of immunogenic cell death for . . .
ABSTRACT Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD) In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemotherapy
- FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with . . .
Lurbinectedin has been approved as second-line treatment for patients with SCLC with platinum-sensitive recurrence as it showed a response rate of 45%, The full sequences of FZ-A038 were provided in the Supplementary Material A linker–payload was synthesized as described in Example 10 of patent WO2020259258A1 ,
- An overview of lurbinectedin as a new second-line treatment . . . - PubMed
Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that carries a poor prognosis Recent approvals with new therapeutic options represent the first in more than a decade for SCLC Lurbinectedin, a newly approved second-line option, is a synthetic alkaloid that co …
- 小细胞肺癌新药芦比替定（Lurbinectedin）临床数据及不良反应
2023年3月23日，国家药监局药品审评中心（CDE）官网公示，绿叶制药申请的注射用芦比替定（通用名：Lurbinectedin）拟纳入优先审评，适用于以铂类为基础的化疗中或化疗后肿瘤进展的转移性小细胞肺癌（SCLC）成人患者的治疗。 此前，2020年6月，PharmaMar公司宣布芦比替定在美国批准上市，用于治疗经过
- An overview of lurbinectedin as a new second-line treatment option for . . .
Lurbinectedin has demonstrated impressive results as a single agent in second-line SCLC, representing the first progress in this setting in more than a decade, and the only new FDA-approval for SCLC other than immunotherapy Lurbinectedin represents a new treatment option in second-line SCLC after approval in the US
- 绿叶制药创新药芦比替定（Lurbinectedin、鲁比卡丁）在中国澳门获批上市：治疗复发性小细胞肺癌 - 知乎
绿叶制药集团 宣布，注射用芦比替定已正式获得中国澳门药物监督管理局的上市批准：用于治疗接受铂类药物化疗期间或期后出现疾病进展的转移性小细胞肺癌（sclc）成人患者。 在中国澳门获批上市后，芦比替定将通过粤港澳大湾区“港澳药械通”政策，进入广东省内19家医疗机构：中山大学附属
- 治疗小细胞肺癌新药——芦比替定(lurbinectedin)
芦比替定是海鞘素(lurbinectedin)的衍生物,也是RNA聚合酶Ⅱ的抑制药,能够与DNA双螺旋结构上小沟共价结合。RNA聚合酶Ⅱ在肿瘤细胞转录过程中往往过度活化,芦比替定可使得肿瘤细胞在有丝分裂过程中畸变、凋亡、最终减少细胞增殖。
|
|
سعر الذهب ، وشراء الذهب ، وبيع الذهب ©2005-2009
|Currency Exchange Rate
|disclaimer
|